Darius Desai retweeted
Dose density 🔋 in #neoadjuvant Tx for #PDAC
A landmark analysis of @SWOG S1505
DD >85% pre or DD >70% periop ➡️OS benefit
Kudos 👏🏽 to investigators and lead author
Dr. Sameer Patel @UCincySurg
@SyedAAhmad5 @DavendraSohal
@OHSUKnight @OHSUpancreatic
dx.doi.org/10.1002/cncr.3575…
Darius Desai retweeted
Less 🩸transfusions for hepatectomy
Multicentre RCT 🇨🇦 by @ChamoGui
👥 446 pts
Phlebotomy 🆚 usual care
⤵️🩸transfusion 16 to 8%
NNT 11 😀
No change in complications
Towards a new standard of care?
📝🔗 thelancet.com/journals/langa… @LancetGastroHep
Darius Desai retweeted
New insights into G2 pancreatic neuroendocrine tumors! Subgrading G2a (Ki67 <10%) vs. G2b (10–20%) reveals distinct behaviors, with G2b showing metastatic potential akin to G3. Read more in @AnnSurgOncol: ow.ly/NVau50UmAWt #FeaturedArticle
Darius Desai retweeted
Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis @JAMAOnc jamanetwork.com/journals/jam…
Darius Desai retweeted
In which @BillKristol makes a direct appeal to the Trump-curious in his life in light of the debate.
"Do you honestly believe this man can and should lead the country for the next four years?"
thebulwark.com/p/the-beginni…
Darius Desai retweeted
Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum @AnnSurgOncol link.springer.com/article/10…
Darius Desai retweeted
Observation of small (≤2cm) panc NETs is widely accepted and becoming a standard. Maybe it is a little more nuanced... Should we take into account tumor grade as well as stage re resection? Small G2 pNETs are more likely than G1 to be N+ (15% vs. 3%).
sciencedirect.com/science/ar…
Darius Desai retweeted
Proud to be co-awarded this @TheVFoundation Translational Research Grant (co-sponsored by @MiamiDolphins) & work closely w/ the superbly talented @PeterHoseinMD. We will uncover an enigmatic mechanism of immunotherapy sensitivity in gHRD mutant #PancreaticCancer #pancsm Let’s go!
This quoted post is unavailable.
Darius Desai retweeted
Most impressive data from #CheckMate9DW (frontline nivo/ipi in #HCC) is the median duration of response: 30.4 months❗️Reaffirms something we've seen time and time again⏩Anti-CTLA4 responses are the most durable
Darius Desai retweeted
New! In press: Prognostic Role of Post-operative #cfDNA after Resection of #ColorectalLiverMetastases: #SystematicReview and #MetaAnalysis . @BeninatoToni @mariameskmd @MiralGrandhiMD @HInMD @RCLanganMD @HenryPittMD @skmaithel ow.ly/rwII50QA0IA
Darius Desai retweeted
🔥ctDNA dynamics in CRC with molecular residual disease
🔎Updated analysis from GALAXY, 2998 pts
👉ctDNA+ post-OP (14%) highly prognostic --> 2yr -OS 29% vs 86%
👉ctDNA clearence --> >90% DFS
🧐Supports ctDNA guided adj. treatment strategies
@myESMO
Darius Desai retweeted
Trial 1 results #NEST
Substantial & brisk responses to just one dose of BOT➕BAL immunotherapy.
Join us on Tuesday January 23rd at 6 PM. @pashtoonkasi will discuss ASCO GI and Trial one results of #NEST. @ASCO #GI24
Darius Desai retweeted
Dr @jordanberlin5 going myth busters from #NET including radiosensitivity, Ki67 predicting biology and intervention randomization and role of SSA #GI23 #GIonc
Darius Desai retweeted
Important secondary analysis of the OPRA trial with a median f/u of 4 years.
This provides important details from a landmark study, and can help guide patient counseling. Of note, it's not broken down to compare induction TNT to consolidation TNT.
My analysis is long-winded, and the target audience is surgeons who offer organ preservation to patients with rectal cancer:
Patients with a cCR at restaging: 98% offered organ preservation/watch-and-wait (WW), of which 22% experienced local regrowth. Patients with a sustained cCR had a 5% rate of distant metastases.
Of the local regrowths, 93% underwent salvage TME and 7% underwent salvage local excision. For these patients, 33% developed recurrence (4% local, 22% distant, and 7% local+distant).
_______________________________________
Patients with a near-complete CR at restaging: 20 (17.5%) went straight to surgery, of which only 3 (16%) had a pathologic CR (pCR). Recurrence after upfront TME for near-cCR was 30% (15% local, 10% distant, 5% local+distant). These numbers were small (n=3 for local recurrence) and should be interpreted with caution.
Of the remaining 94 patients (82.5%) who underwent WW, 48 (51%) developed local regrowth. Salvage TME was performed in 34 patients (71% compared to 93% for cCRs). 2 of 34 TMEs (6%) had a pCR.
For patients with a near-cCR who developed regrowth after WW, 33% developed recurrence (4% local, 21% distant, 8% local+distant).
Of the 46 patients (40%) with a near-cCR who remained in the WW program, 13% developed distant metastases (compared to 5% for cCRs).
______________________________________
Patients with an incomplete response at restaging:
88% were offered upfront TME, of which 4/51 (8%) had a pCR. For ICR and upfront TME, recurrence rate was 35% (3.5% local, 21% distant, 10.5% local+distant).
8 patients with incomplete response were still enrolled in WW for different reasons, of which 5/8 (63%) developed local regrowth. All 5 underwent TME, and the local recurrence was 20% (1/5). Of the 3/8 that remained in WW without regrowth, 2/3 (66%) developed lung metastases.
_______________________________________
Overall, the 3-year organ preservation rate was 77% for cCRs and 40% for near-cCRs. The median time to TME for near-cCRs was 1 year.
3-year DFS was 88% for cCR, 69% for near-cCR, and 56% for incomplete response.
_____________________________
For patient counseling purposes:
Of the 123 patients with a cCR who were offered WW, the local recurrence rate was 22% (0f which 93% underwent salvage TME) and the rate of distant metastasis was 10.5%.
Of the 94 patients with a near-cCR who were offered WW, local recurrence rate was 51% (of which 71% underwent salvage TME) and the rate of distant metastasis was 15%.
Of the 57 patients with incomplete response who were offered upfront TME, local recurrence was 14% and the rate of distant metastasis was 32%.
@JohnRTMonsonMD @R_Perez_MD @ianmpaquette @JonVogel7 @jendavidsmd @KyleCologne @debby_keller @juliomayol @Neil_J_Smart @FergaljFleming @ScottRSteeleMD @JISBMD
This Post is from a suspended account. Learn more
Darius Desai retweeted
This @AnnSurgOncol #FeaturedArticle found that combined hepatic artery infusion and modern systemic therapy in chemotherapy-naive patients with unresectable CRLM resulted in durable and substantial response in a large proportion of patients.
📃: ow.ly/J98R50Q6A7Y
Darius Desai retweeted
Effect of #AnastomoticLeak on Long-Term Survival After #Esophagectomy : Multivariate Meta-analysis and Restricted Mean Survival Times Examination @AlbertoAiolfi
rdcu.be/dqwBP
Darius Desai retweeted
PUBLISHED: #CirculatingTumorCells are an Independent Risk Factor for Poor Prognosis in Patients with #GallbladderAdenocarcinoma. rdcu.be/dlqiN @SocSurgOnc
Darius Desai retweeted
AUGUST ISSUE: Oncological Outcome After #LymphNodeDissection for #CutaneousSquamousCellCarcinoma. rdcu.be/dhJXu @SocSurgOnc



































